Summary
Overview
Work History
Education
Skills
Affiliations
Publications
Timeline
Generic

Joe Orlando, Ph.D.

Waltham,MA

Summary

Experienced professional with over 15 years of Industrial experience in Research and Development. Proven track record of leading cross-functional teams to develop and commercialize innovative products that meet FDA regulations. Passionate about driving innovation in genomic medicine to improve patient outcomes.

Overview

23
23
years of professional experience

Work History

Senior R&D Director, Head of Innovation

MilliporeSigma, CDMO
Bedford, MA
07.2022 - Current
  • Led development and execution of internal R&D Innovation Strategy for Viral Vector and Recombinant Protein Service Business.
  • Lead multi-site team of R&D scientists responsible for bringing innovative improvements to operations at the CDMO from concept to service launch. Two service offering launches achieved in 2023.
  • Set, monitor, and report Innovation metrics to Senior Leadership, i.e. New Product Sales, Program Financials, and Launch.
  • Drive Collaboration across large network of Merck to enhance both Product and Service offerings for Viral Vector and Recombinant Protein markets.
  • Shorten client timelines to expedite delivery of life-saving therapies to patients in need.

R&D Director, Head of Cell and Gene Therapies

MilliporeSigma
Bedford, MA
05.2020 - 07.2022
  • Built and managed new R&D team composed of 30+ scientists and engineers.
  • Led team that conceived, developed and launched products for viral vector Bioprocessing including host cell lines & cell culture media for LV, AAV & Ad BioProcessing, and products for Cell Therapy Bioprocessing including purification systems and cell culture media.
  • Built internal feedstream service for LV and AAV to support company R&D efforts.
  • Drove collaborations with Filtration and Chromatography teams to adapt existing technologies or develop new devices to capture Novels Market.
  • Company leader for multiple industry Consortia including BPOG and NIIMBL.

Senior R&D Manager

MilliporeSigma
Bedford, MA
04.2017 - 05.2020
  • Led team of 10+ Scientists and Engineers focused on Recombinant Protein Process Development and BioProduction.
  • Led research effort for Advanced Cell Line Development product launch in 2020.
  • Drove development of Integrated Product offering to simplify Bioprocessing, improve Product reach and reduce client timelines.
  • Manage internal Upstream Feedstream service that delivered >2000 L of Biologics/year for product development and application data.

Principal Scientist

MilliporeSigma
Bedford, MA
06.2012 - 04.2017
  • Led team of scientists and engineers focused on Upstream BioProcessing.
  • Project lead for cell line development and PD efforts for mAb and biosimilar expression. Established lines expressing >5 g/L mAb and process conditions that produced product with high similarity to the originator.
  • Cooperated with business partners to establish Upstream R&D strategy for product business.
  • Supported Service Business by establishing Cell Line Development Platform; and leading client cell line development & PD projects.

Senior Scientist

MilliporeSigma
Bedford, MA
05.2007 - 06.2012
  • Established center of excellence for Cell and Molecular Biology.
  • Developed, evaluated and launched Expression Vectors for mAb Expression. Responsible for customer relations with over 20 corporations.
  • Designed modified Protein A ligand for mAb BioProcessing, patented the design, supported product development, testing, cell banking and launch.
  • Led team that evaluated novel technologies for BioProcessing including metabolomics, targeted gene insertion and high-throughput screening systems.

Post-doctoral Fellow

Harvard Medical School
Boston, MA
06.2001 - 05.2007
  • Studied mechanisms of cell metabolism inhibition by Herpes Simplex Virus.
  • Obtained funding from the National Cancer Institute (F32 CA99887).
  • Five peer-reviewed publications and podium presentations at International conferences.
  • Managed lab technicians, graduate students and undergraduates.

Education

Ph.D. - Microbiology and Immunology

Wake Forest University
Winston-Salem, NC

M.S. Biotechnology - Kellogg School of Management

Northwestern University

B.S. Chemistry - Biology Minor

Millsaps College

Skills

  • Research and Development
  • Innovation
  • Product Development
  • Commercialization
  • Strategic Planning
  • Product Launch
  • Science Mindset
  • Problem Solving
  • Program and Team Leader
  • Cross Functional Collaboration

Affiliations

  • Simplify and Accelerate the Path to Viral Vector Manufacture with the VirusExpress® LV and AAV Production Platforms, BioProcess International, Boston MA 2023
  • A Rapid Path to Viral Vector Manufacturing using the VirusExpress®Production Platform, ASGCT, Los Angeles 2023.
  • Rapid, High Performance Cell Line Development, BioProcess International, Boston Ma 2019

Publications

· Demonstrating Process Scalability, AUGUST 2018 Genetic Engineering & Biotechnology News 22-23, Orlando JS

· Ubiquitous Chromatin-opening Elements (UCOEs): Applications in biomanufacturing and gene therapy. Biotechnol Adv. 2017 Sep;35(5):557-564. Neville JJ, Orlando JS, Mann K, McCloskey B, Antoniou MN.

· A new paradigm for transcription factor TFIIB functionality. Nature, Sci Rep. 2014 Jan 20;(4):3664 Gelev V, Zabolotny JM, Lange M, Hiromura M, Yoo SW, Orlando JS, Kushnir A, Horikoshi N, Paquet E, Bachvarov D, Schaffer PA, Usheva A. (2014)

· Transient expression of herpes simplex virus type 1 ICP22 represses viral promoter activity and complements the replication of an ICP22 null virus. J Virol. Sep;83(17):8733-43. Bowman JJ, Orlando JS, Davido DJ, Kushnir AS, Schaffer PA (2009)

· ICP22 is Required for Wild-type Composition and Infectivity of Herpes Simplex Virus Type 1 Virions. Journal of Virology. 80:9381-9390. Orlando JS, Balliet JB, Kushnir AS, Rice SA, Knipe D, and PA Schaffer (2006)

· Products of the Herpes Simplex Virus Type-1 Immediate Early US1/US1.5 Genes Downregulate Levels of S Phase-specific Cyclins and Facilitate Virus Replication in S Phase Vero Cells. Journal of Virology. 80:4005-4016. Orlando JS, Astor TL, Rundle SA and PA Schaffer. (2006)

· The Ad E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. Journal of Biological Chemistry. 280(2):1474-81. Hart LS, Yannone SM, Naczki C, Orlando JS, Waters SB, Akman SA, Chen DJ, Ornelles D, C Koumenis. (2005)

· E4orf6 variants with separate abilities to augment virus replication and direct nuclear localization of the E1B-55 kDa protein. Journal of Virology. 76:1475-1487. Orlando JS and DA Ornelles. (2002)

· An arginine-faced amphipathic a helix is required for adenovirus type 5 E4orf6 protein function. Journal of Virology. 73:4600-4610. Orlando JS and DA Ornelles. (1999)

Timeline

Senior R&D Director, Head of Innovation

MilliporeSigma, CDMO
07.2022 - Current

R&D Director, Head of Cell and Gene Therapies

MilliporeSigma
05.2020 - 07.2022

Senior R&D Manager

MilliporeSigma
04.2017 - 05.2020

Principal Scientist

MilliporeSigma
06.2012 - 04.2017

Senior Scientist

MilliporeSigma
05.2007 - 06.2012

Post-doctoral Fellow

Harvard Medical School
06.2001 - 05.2007

Ph.D. - Microbiology and Immunology

Wake Forest University

M.S. Biotechnology - Kellogg School of Management

Northwestern University

B.S. Chemistry - Biology Minor

Millsaps College

Similar Profiles

CREATE PROFILE
Joe Orlando, Ph.D.